Stelara gains EU positive opinion
This article was originally published in Scrip
Executive Summary
Janssen-Cilag(Johnson & Johnson) has received a positive opinion from the CHMPfor its novel immunological product Stelara (ustekinumab), 45mg or 90mg powder for solution for injection, for the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to, are intolerant to, or have a contraindication to other systemic therapies including ciclosporin, methotrexate and psoralen plus ultraviolet A light.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.